Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Takeda's lapaquistat delayed

Takeda (Tokyo:4502) said a planned 2Q08 NDA submission for lapaquistat (TAK-475)

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE